COMPANY PROFILE // THE 014 REPORT
Inhibikase Therapeutics, Inc.
IKT (Nasdaq)
Assembled from 3 government sources in 3.3 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2026-08-26 (last 24 months).
- InfoGLEIF: no direct parent reported; reporting exception reason NON_CONSOLIDATING.
- InfoRegistered business address (1000 N. WEST STREET, SUITE 1200, WILMINGTON) is shared with 10 other entities in our records (SEC registrants and IRS-registered organizations).
- InfoUSAspending recipient E5PSKKJUHEW4 (matched to this company by exact name) has no entity registration in the SAM.gov public extract of 2026-11-01.possible match
✓ SEC filings✓ LEI✓ State registrationpossible match✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no website, no lobbying registration on record; address shared with 10 entities.
Inhibikase Therapeutics, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in Wilmington, DE; listed as IKT (Nasdaq).[source] It reported revenue of $0 for the fiscal year ended 2024-12-31.[source] It has filed 62 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-11-10.[source] Its largest institutional holders on 13F filings are Sands Capital Alternatives, LLC, Soleus Capital Management, L.P., Trails Edge Capital Partners, LP (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 8-K Item 4.01 filed.[source]
- red0
- amber1
- info3
- Sands Capital Alternatives, LLC$26.4M
- Soleus Capital Management, L.P.$22.1M
- Trails Edge Capital Partners, LP$18.4M
- Fairmount Funds Management LLC$17.5M
- BlackRock, Inc.$15.8M
- Kalehua Capital Management LLC$15.5M
- ADAR1 Capital Management, LLC$15.0M
- Blackstone Inc.$12.1M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Cabell Christopher · President & Head of R&D (Officer) · latest Form 4 2026-02-24 · filing · LinkedIn search
- Iwicki Mark T · Chief Executive Officer (Director,Officer) · latest Form 4 2026-01-07 · filing · LinkedIn search
- McIntyre David · Chief Financial Officer (Officer) · latest Form 4 2026-01-07 · filing · LinkedIn search
- Aurentz Vincent · Director · latest Form 4 2026-02-24 · filing · LinkedIn search
- BERMAN DENNIS N · Director · latest Form 4 2025-07-02 · filing · LinkedIn search
- Bellini Roberto · Director · latest Form 4 2025-07-02 · filing · LinkedIn search
- Canner David · Director · latest Form 4 2025-07-02 · filing · LinkedIn search
- Kush Arvind · Director · latest Form 4 2025-07-02 · filing · LinkedIn search
- Munshi Amit · Director · latest Form 4 2026-02-24 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Goodwin Procter LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-08-11
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001750149 | source |
| LEI | 549300066CFEWOA17F12 | source |
| UEIpossible match | E5PSKKJUHEW4 | source |
| EIN | 26-3407249 | source |
| NY DOS ID | 7947629 | record |
| Business address (SEC) | 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DE, 19801 | source |
Does not exist in the records we hold: FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-08-29 · in 282 days · LEI next renewal (549300066CFEWOA17F12)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
ADDRESS · ZIP CODE
Location context
At the same address (11)
- ACORN ENERGY, INC. · SEC registrant
- Marvell Technology, Inc. · SEC registrant
- GOLDEN OPPORTUNITIES FOUNDATION · IRS-registered organization
- THE QUEEN 1789 FOUNDATION INC · IRS-registered organization
- WESTERN WIND FOUNDATION · IRS-registered organization
- APACHE SOFTWARE FOUNDATION · IRS-registered organization
- DDX3X FOUNDATION · IRS-registered organization
- HARRY AND JANE SAVILLE SMITH FOUNDATION · IRS-registered organization
- FUTURE SOCCER STARTS FOUNDATION · IRS-registered organization
- MSR FOUNDATION USA INC · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- KALA BIO, Inc. · Iwicki Mark T
- Q32 Bio Inc. · Iwicki Mark T
- Arcutis Biotherapeutics, Inc. · Munshi Amit
- Damora Therapeutics, Inc. · Munshi Amit
- Zura Bio Ltd · Munshi Amit
SEC registrants at the same address
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-10 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-10 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-20 officer change 8-K items 5.02,7.01,9.01 · SEC EDGAR
- 2026-09-08 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-08-26 filing 8-K items 4.01,9.01 · SEC EDGAR
- 2026-08-11 filing S-8 · SEC EDGAR
- 2026-08-11 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-11 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-29 filing 8-K items 3.02,9.01 · SEC EDGAR
- 2026-07-23 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-07-14 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-06-29 officer change 8-K items 5.02,5.03,5.07,9.01 · SEC EDGAR
- 2026-05-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-30 filing ARS · SEC EDGAR
- 2026-04-30 filing DEFA14A · SEC EDGAR
- 2026-04-30 filing Proxy statement · SEC EDGAR
- 2026-04-20 filing PRE 14A · SEC EDGAR
- 2026-04-07 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-03-26 filing S-8 · SEC EDGAR
- 2026-03-26 filing Annual report (10-K) · SEC EDGAR
- 2026-03-26 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-12-19 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2025-12-19 filing 424B5 · SEC EDGAR
- 2025-11-21 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2025-11-21 filing 424B5 · SEC EDGAR
- 2025-11-20 filing 424B5 · SEC EDGAR
- 2025-11-20 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2025-11-14 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-11-14 filing 8-K items 2.02,9.01 · SEC EDGAR
170 earlier entries
- 2025-08-28 filing 3/A
- 2025-08-28 filing 3/A
- 2025-08-14 filing Quarterly report (10-Q)
- 2025-08-14 filing 8-K items 2.02,7.01,9.01
- 2025-07-15 filing 3/A
- 2025-07-02 insider First Form 3/4/5 on record for Cabell Christopher (President & Head of R&D)
- 2025-07-02 insider First Form 3/4/5 on record for Iwicki Mark T (Chief Executive Officer)
- 2025-07-02 insider First Form 3/4/5 on record for Aurentz Vincent (Director)
- 2025-07-02 insider First Form 3/4/5 on record for BERMAN DENNIS N (Director)
- 2025-07-02 insider First Form 3/4/5 on record for Bellini Roberto (Director)
- 2025-07-02 insider First Form 3/4/5 on record for Canner David (Director)
- 2025-07-02 insider First Form 3/4/5 on record for Kush Arvind (Director)
- 2025-07-02 insider First Form 3/4/5 on record for Munshi Amit (Director)
- 2025-06-30 filing 8-K items 5.07
- 2025-06-27 filing EFFECT
- 2025-06-25 filing CORRESP
- 2025-06-25 filing UPLOAD
- 2025-06-20 filing S-3
- 2025-06-12 filing DEFA14A
- 2025-05-14 filing Quarterly report (10-Q)
- 2025-05-14 filing 8-K items 2.02,9.01
- 2025-05-12 filing ARS
- 2025-05-12 filing DEFA14A
- 2025-05-12 filing Proxy statement
- 2025-05-02 filing PRE 14A
- 2025-04-25 filing 10-K/A
- 2025-04-16 insider First Form 3/4/5 on record for McIntyre David (Chief Financial Officer)
- 2025-04-14 officer change 8-K items 5.02,7.01,9.01
- 2025-03-27 filing S-8
- 2025-03-27 filing Annual report (10-K)
- 2025-03-27 filing 8-K items 2.02,9.01
- 2025-02-24 officer change 8-K items 1.01,3.02,5.02,7.01,9.01
- 2025-02-18 officer change 8-K items 5.02,7.01,9.01
- 2025-02-04 filing S-8
- 2025-01-29 filing 8-K items 8.01
- 2025-01-16 filing EFFECT
- 2025-01-14 filing CORRESP
- 2025-01-14 filing UPLOAD
- 2025-01-10 filing S-3
- 2025-01-06 filing 8-K items 5.03,5.07,9.01
- 2024-12-05 filing EFFECT
- 2024-12-05 filing 8-K items 1.02
- 2024-12-05 filing 424B3
- 2024-12-03 filing CORRESP
- 2024-12-03 filing S-3/A
- 2024-11-18 filing S-3
- 2024-11-18 filing Proxy statement
- 2024-11-14 filing Quarterly report (10-Q)
- 2024-11-08 filing PRE 14A
- 2024-10-22 officer change 8-K items 1.01,5.02,7.01,9.01
- 2024-10-11 filing SC 14F1
- 2024-10-10 officer change 8-K items 1.01,3.02,5.02,7.01,8.01,9.01
- 2024-10-09 filing 8-K items 7.01,9.01
- 2024-08-14 filing Quarterly report (10-Q)
- 2024-08-06 filing 8-K items 5.07
- 2024-06-27 filing 424B3
- 2024-06-26 filing EFFECT
- 2024-06-24 filing CORRESP
- 2024-06-21 filing DEFA14A
- 2024-06-21 filing UPLOAD
- 2024-06-20 filing Proxy statement
- 2024-06-18 filing Registration (S-1)
- 2024-06-10 filing PRE 14A
- 2024-06-10 filing 8-K items 5.07
- 2024-06-04 filing D
- 2024-05-22 filing 424B5
- 2024-05-20 filing 8-K items 1.01,3.02,7.01,9.01
- 2024-05-20 filing 424B5
- 2024-05-15 filing Quarterly report (10-Q)
- 2024-05-15 filing RW
- 2024-05-09 filing S-1/A
- 2024-05-09 filing S-1/A
- 2024-04-30 filing 8-K items 7.01,8.01,9.01
- 2024-04-29 filing S-1/A
- 2024-04-26 filing DEFA14A
- 2024-04-26 filing ARS
- 2024-04-26 filing Proxy statement
- 2024-04-25 filing S-1/A
- 2024-04-19 filing Registration (S-1)
- 2024-04-19 filing 8-K items 7.01,9.01
- 2024-04-15 filing PRE 14A
- 2024-04-02 officer change 8-K/A items 5.02,9.01
- 2024-03-27 filing Annual report (10-K)
- 2024-02-07 filing 8-K items 8.01,9.01
- 2024-02-01 filing 424B5
- 2024-02-01 filing 8-K items 1.01,9.01
- 2024-01-16 officer change 8-K items 5.02,9.01
- 2023-11-14 filing Quarterly report (10-Q)
- 2023-10-16 filing 10-K/A
- 2023-09-20 filing 8-K items 7.01,9.01
- 2023-08-14 filing Quarterly report (10-Q)
- 2023-07-17 filing 8-K items 8.01,9.01
- 2023-06-29 filing 8-K items 3.03,5.03,7.01,9.01
- 2023-06-28 filing 8-K items 5.07
- 2023-05-15 filing Quarterly report (10-Q)
- 2023-05-12 filing DEFA14A
- 2023-05-05 filing ARS
- 2023-05-05 filing Proxy statement
- 2023-04-21 filing PRE 14A
- 2023-04-04 filing EFFECT
- 2023-04-04 filing 424B3
- 2023-03-31 filing POS AM
- 2023-03-31 filing Annual report (10-K)
- 2023-03-22 filing 8-K items 7.01,9.01
- 2023-03-13 filing 8-K items 8.01
- 2023-03-06 officer change 8-K items 5.02
- 2023-02-24 filing SC 13D
- 2023-02-08 filing 424B3
- 2023-02-07 filing EFFECT
- 2023-02-07 filing D
- 2023-02-03 filing UPLOAD
- 2023-02-03 filing CORRESP
- 2023-02-02 filing Registration (S-1)
- 2023-01-31 filing SC 13D
- 2023-01-27 filing 424B5
- 2023-01-26 filing 8-K items 1.01,1.02,3.02,7.01,9.01
- 2023-01-25 filing 8-K items 8.01,9.01
- 2023-01-24 filing 8-K items 3.01
- 2022-11-17 filing 8-K items 2.02,9.01
- 2022-11-14 filing Quarterly report (10-Q)
- 2022-11-07 filing 8-K items 8.01,9.01
- 2022-09-16 filing 8-K items 7.01,9.01
- 2022-09-01 officer change 8-K items 5.02,7.01,9.01
- 2022-08-15 filing 8-K items 7.01,9.01
- 2022-08-12 filing Quarterly report (10-Q)
- 2022-07-29 filing 8-K items 3.01
- 2022-06-29 filing 8-K items 5.07
- 2022-06-22 filing DEFR14A
- 2022-05-17 filing 8-K items 1.01,9.01
- 2022-05-17 filing 424B5
- 2022-05-16 filing Quarterly report (10-Q)
- 2022-05-03 filing DEFA14A
- 2022-05-02 filing Proxy statement
- 2022-04-21 filing PRE 14A
- 2022-04-21 filing 8-K items 7.01,9.01
- 2022-03-31 filing Annual report (10-K)
- 2022-03-24 filing 8-K items 7.01,9.01
- 2022-03-21 officer change 8-K/A items 5.02,9.01
- 2022-03-08 officer change 8-K items 5.02,9.01
- 2022-02-11 filing EFFECT
- 2022-02-09 filing CORRESP
- 2022-02-09 filing UPLOAD
- 2022-02-07 filing S-3
- 2022-01-20 filing 8-K items 7.01,9.01
- 2022-01-11 filing SC 13D
- 2021-12-15 filing SC 13D
- 2021-11-15 filing Quarterly report (10-Q)
- 2021-10-19 filing 8-K items 7.01,9.01
- 2021-09-15 filing S-8
- 2021-09-08 filing 8-K items 8.01
- 2021-08-17 filing 8-K items 7.01,9.01
- 2021-08-16 filing Quarterly report (10-Q)
- 2021-06-29 filing 8-K items 5.07
- 2021-06-21 filing SC 13D
- 2021-06-21 filing 8-K items 7.01,9.01
- 2021-06-17 filing 424B4
- 2021-06-16 filing 8-K items 1.01,9.01
- 2021-06-15 filing EFFECT
- 2021-06-11 filing CORRESP
- 2021-06-11 filing CORRESP
- 2021-06-11 filing Registration (S-1)
- 2021-06-03 filing UPLOAD
- 2021-06-02 filing DRS
- 2021-06-01 filing 8-K items 7.01,9.01
- 2021-05-17 filing Quarterly report (10-Q)
- 2021-04-30 filing DEFA14A
- 2021-04-30 filing Proxy statement
- 2021-04-01 filing 8-K items 2.02,9.01
- 2021-03-31 filing Annual report (10-K)
- 2021-02-08 filing 8-K items 7.01,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-10 (within 30 days) 10-Q filed
- 2026-11-10 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-20 (older) 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-08 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-26 (older) 8-K filed: Item 4.01 auditor change; Item 9.01 exhibits
- 2026-08-11 (older) S-8 filed
- 2026-08-11 (older) 10-Q filed
- 2026-08-11 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:IKT The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
4 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1750149 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | IKT / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 549300066CFEWOA17F12 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300066CFEWOA17F12) | GLEIF |
| EIN | 263407249 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001750149 | SEC EDGAR / IRS |
| CUSIP | 45719W205 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001750149 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2024-12-31) | $0 | 2024-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-20 09:59 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$48,259,189 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 09:59 UTC | Report an error |
| Total assets (at 2025-12-31) | $181,204,516 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 09:59 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $172,903,679 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 09:59 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $178,800,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 09:59 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 09:59 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 09:59 UTC | Report an error |
| State of incorporation | DE | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 09:59 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 09:59 UTC | Report an error |
| Business address | 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DE, 19801 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 09:59 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 09:59 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$27,786,464 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 09:59 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $13,399 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 09:59 UTC | Report an error |
| Operating lease liabilities (at 2024-12-31) | $110,517 | 2024-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 09:59 UTC | Report an error |
| Form D total offering amount (D filed 2024-06-04) | $7,999,999 | 2024-06-04 | D | as filed | 2026-11-20 09:59 UTC | Report an error |
| Form D total amount sold (D filed 2024-06-04) | $0 | 2024-06-04 | D | as filed | 2026-11-20 09:59 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2024-06-04 | D | as filed | 2026-11-20 09:59 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2024-06-04 | D | as filed | 2026-11-20 09:59 UTC | Report an error |
| Form D date of first sale | 2024-05-20 | 2024-06-04 | D | as filed | 2026-11-20 09:59 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-10 · accession 0001193125-26-455625
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$20,467,334 | 3 months ended 2026-09-30 | 10-Q | 2026-11-10 | 0001193125-26-455625 | 2026-11-20 09:59 UTC | Report an error |
| Cash and cash equivalents | $51,701,197 | at 2026-09-30 | 10-Q | 2026-11-10 | 0001193125-26-455625 | 2026-11-20 09:59 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-10 Filing 10-Q filed
- 2026-11-10 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-20 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-08 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-26 Filing 8-K filed: Item 4.01 auditor change; Item 9.01 exhibits
- 2026-08-11 Filing S-8 filed
- 2026-08-11 Filing 10-Q filed
- 2026-08-11 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-29 Filing 8-K filed: Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-07-23 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-14 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-06-29 Filing 8-K filed: Item 5.02 officer or director change; Item 5.03 charter or bylaw amendment; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-05-12 Filing 10-Q filed
- 2026-05-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-30 Filing ARS filed
- 2026-04-30 Filing DEFA14A filed
- 2026-04-30 Filing DEF 14A filed
- 2026-04-20 Filing PRE 14A filed
- 2026-04-07 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-03-26 Filing S-8 filed
- 2026-03-26 Filing 10-K filed
- 2026-03-26 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-12-19 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2025-12-19 Filing 424B5 filed
- 2025-11-21 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | Sands Capital Alternatives, LLC | $26,428,499 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:59 UTC | Report an error |
| 2 | Soleus Capital Management, L.P. | $22,076,250 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:59 UTC | Report an error |
| 3 | Trails Edge Capital Partners, LP | $18,374,176 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:59 UTC | Report an error |
| 4 | Fairmount Funds Management LLC | $17,508,750 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:59 UTC | Report an error |
| 5 | BlackRock, Inc. | $15,769,155 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:59 UTC | Report an error |
| 6 | Kalehua Capital Management LLC | $15,516,874 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:59 UTC | Report an error |
| 7 | ADAR1 Capital Management, LLC | $14,996,026 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:59 UTC | Report an error |
| 8 | Blackstone Inc. | $12,054,700 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:59 UTC | Report an error |
| 9 | Siren, L.L.C. | $11,875,500 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:59 UTC | Report an error |
| 10 | Nantahala Capital Management, LLC | $10,969,564 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:59 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- INHIBIKASE THERAPEUTICS, INC. · LEI 549300066CFEWOA17F12 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
4 state and city records carry this company's exact name, from 4 sources. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchInhibikase Therapeutics · exact name match to 'Inhibikase Therapeutics, Inc.' (no other entity shares the name) · sx:ctgov:h162a00aed529f478 Compare
State licences (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchINHIBIKASE THERAPEUTICS, INC. · exact legal name · sx:elic:ctcred:2663280 Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchINHIBIKASE THERAPEUTICS, INC. · exact legal name · sx:nydos:7947629 Compare
USAspending (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchINHIBIKASE THERAPEUTICS, INC. · exact legal name · sx:usaspending:E5PSKKJUHEW4 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1750149.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001750149. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.